Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brimonidine tartrate/ketotifen fumarate - Bausch & Lomb

Next Previous
Drug Profile

Brimonidine tartrate/ketotifen fumarate - Bausch & Lomb

Alternative Names: Brimonidine tartrate/ketotifen fumarate

Latest Information Update: 11 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bausch & Lomb
  • Class Antiallergics; Antiglaucomas; Antihypertensives; Bromobenzenes; Diamines; Eye disorder therapies; Imidazoles; Piperidines; Quinoxalines; Sedating antihistamines; Skin disorder therapies; Small molecules; Thiophenes
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Histamine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Allergic conjunctivitis

Most Recent Events

  • 04 Aug 2023 Bausch & Lomb completes a phase III trial for Allergic conjunctivitis (In adults) in USA (Ophthalmic, Suspension) (NCT05591755)
  • 22 Jul 2023 Bausch & Lomb completes a phase III trial for Allergic conjunctivitis (In adults, In children) in USA (Ophthalmic, Suspension) (NCT05579730)
  • 26 May 2023 Chemical structure information added

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top